Compare DMRC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRC | ENTX |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.5M | 147.4M |
| IPO Year | 2026 | 2015 |
| Metric | DMRC | ENTX |
|---|---|---|
| Price | $5.61 | $3.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $9.00 |
| AVG Volume (30 Days) | 108.2K | ★ 335.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.27 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.07 | $0.91 |
| 52 Week High | $17.47 | $4.20 |
| Indicator | DMRC | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 50.66 |
| Support Level | $5.57 | $2.66 |
| Resistance Level | $7.10 | $3.10 |
| Average True Range (ATR) | 0.55 | 0.23 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 22.49 | 13.17 |
Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.